Mirati Therapeutics Pipeline Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to ultimately help improve the lives of patients with cancer. Each of our programs is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. Click on each program to learn more. Adagrasib (MRTX849) KRASG12C Inhibitor Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation. Development Approach Lead Optimization IND-Enabling Phase 1/1b Phase 2 Phase 3 Monotherapy 2L+NSCLC, CRC, Other 1L NSCLC: STK11 Co-Mutation 2L NSCLC (Randomized to Docetaxel) Combination with Pembrolizumab (PD-1) 1L NSCLC (2 Arms: <1% TPS and ≥1% TPS) Combination with Cetuximab (EGFR) 2L CRC (Randomized to FOLFIRI or FOLFOX) POC Combinations: SHP2, SOS1, Pan-EGFR, CDK4/6 2L+ NSCLC & CRC (Proof of Concept (POC)) MRTX1133 KRASG12D Inhibitor MRTX1133 is an investigational, highly selective and potent small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with high unmet need. Development Approach Lead Optimization IND-Enabling Phase 1/1b Phase 2 Phase 3 Monotherapy Pancreatic, CRC, NSCLC, Other Sitravatinib Multi Kinase Inhibitor Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can potentially stimulate the body’s immune response to fight cancer. Development Approach Lead Optimization IND-Enabling Phase 1/1b Phase 2 Phase 3 PD-1 2/3L NS-NSCLC (SAPPHIRE – Nivolumab Combination) NSCLC, Other — Various Combination Studies with Tislelizumab1 MRTX1719 Synthetic Lethal PRMT5 Inhibitor Development Approach Lead Optimization IND-Enabling Phase 1/1b Phase 2 Phase 3 Monotherapy MTAP-Deleted Cancers Discovery Programs Development Approach Lead Optimization IND-Enabling Phase 1/1b Phase 2 Phase 3 SOS1 Inhibitor (KRAS Signal Modifying) Solid Tumors Mutant KRAS Inhibitor Solid Tumors NSCLC: non-small cell lung cancer; CRC: colorectal cancer; OS = Overall Survival; NS = non-squamous; IND = investigational new drug MTAP: methylthioadenosine phosphorylase 1. BeiGene is currently conducting certain combination studies of sitravatinib + tislelizumab (their anti-PD-1) in Asia for solid tumor indications including NSCLC, hepatocellular carcinoma, renal cell carcinoma, ovarian and gastric cancers. BeiGene has the Asian commercialization rights (ex-Japan) for sitravatinib as part of our development and commercialization agreement and is responsible for additional data disclosures. Mirati Therapeutics © Copyright 2021 - Mirati Therapeutics, Inc. 858.332.3410 info@mirati.com Terms of Use Privacy Cookies Expanded Access Community Guidelines